--- title: "Lantheus Holdings (LNTH) news: merger" url: "https://aibio.space/companies/lantheus/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "LNTH merger news: Lantheus discloses three stockholder suits over its Curium merger and 16 demand letters. Lantheus Holdings, Inc." --- LNTH Lantheus Holdings, Inc. NASDAQ · United States # Lantheus Holdings (LNTH) news LNTH merger news Legal · 2026-10-02 ## [Lantheus discloses three stockholder suits over its Curium merger and 16 demand letters](https://aibio.space/news/lantheus-discloses-three-stockholder-suits-curium-merger-16-demand/) Defendants: Lantheus Holdings and unnamed Board members, per the 8-K. Two New York and one Massachusetts complaint allege proxy omissions; the company says they lack merit. ## Latest Lantheus Holdings news 1. 2025-07-22 Mergers [Lantheus completes Life Molecular Imaging acquisition with $350 million upfront payment](https://aibio.space/news/lantheus-completes-life-molecular-imaging-acquisition-350-million/) Lantheus closed the acquisition on July 21, 2025 and named Dr. Ludger Dinkelborg Head of Research and Development, effective August 1, 2025. The deal adds the Alzheimer's PET imaging agent Neuraceq. 2. 2025-04-01 Mergers [Lantheus completes Evergreen Theragnostics acquisition, paying about $275 million in cash](https://aibio.space/news/lantheus-completes-evergreen-theragnostics-acquisition-paying-about/) Lantheus said on April 1, 2025 that it completed its acquisition of Evergreen Theragnostics, paying about $275 million in cash at closing. That is a $250 million upfront payment plus a $25 million milestone, and up to $727.5 million in further milestone payments remain possible. ## Lantheus Holdings at a glance - **Ticker**: LNTH - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $593.3 million ### Related companies - [Dermata Therapeutics](https://aibio.space/companies/dermata-therapeutics/) NASDAQ: DRMA - [CervoMed](https://aibio.space/companies/cervomed/) NASDAQ: CRVO - [Apollomics](https://aibio.space/companies/apollomics/) NASDAQ: APLM - [Organogenesis Holdings](https://aibio.space/companies/organogenesis/) NASDAQ: ORGO - [Nutriband](https://aibio.space/companies/nutriband/) NASDAQ: NTRB - [Celularity](https://aibio.space/companies/celularity/) NASDAQ: CELU - [Impact BioMedical](https://aibio.space/companies/impact-biomedical/) AMEX: IBO - [Endovia Health Sciences](https://aibio.space/companies/endovia-health-sciences/) AMEX: EDVA ### Also on NASDAQ - [Nkarta](https://aibio.space/companies/nkarta/) NKTX - [Tempus AI](https://aibio.space/companies/tempus-ai/) TEM - [Xeris Biopharma Holdings](https://aibio.space/companies/xeris-biopharma/) XERS - [NextCure](https://aibio.space/companies/nextcure/) NXTC - [Precision BioSciences](https://aibio.space/companies/precision-biosciences/) DTIL - [C4 Therapeutics](https://aibio.space/companies/c4-therapeutics/) CCCC ## Lantheus Holdings annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$177.3 million](https://www.sec.gov/Archives/edgar/data/1521036/000119312526073498/) | [$168.1 million](https://www.sec.gov/Archives/edgar/data/1521036/000119312526073498/) | | Net income (loss) | [$233.6 million](https://www.sec.gov/Archives/edgar/data/1521036/000119312526073498/) | [$312.4 million](https://www.sec.gov/Archives/edgar/data/1521036/000119312526073498/) | | Cash from operations | [$390.1 million](https://www.sec.gov/Archives/edgar/data/1521036/000119312526073498/) | [$544.8 million](https://www.sec.gov/Archives/edgar/data/1521036/000119312526073498/) | | Cash and equivalents | [$359.1 million](https://www.sec.gov/Archives/edgar/data/1521036/000119312526336795/) | [$912.8 million](https://www.sec.gov/Archives/edgar/data/1521036/000119312526073498/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $593.3 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Lantheus Holdings Is Lantheus Holdings involved in a merger or acquisition? Our latest story on this, dated Oct 2, 2026: "Lantheus discloses three stockholder suits over its Curium merger and 16 demand letters". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/lantheus-discloses-three-stockholder-suits-curium-merger-16-demand/). What is the ticker symbol of Lantheus Holdings? Lantheus Holdings, Inc. trades under the ticker LNTH on NASDAQ. Where is Lantheus Holdings listed? Lantheus Holdings, Inc. is listed on NASDAQ. What is the SEC CIK of Lantheus Holdings? The SEC Central Index Key (CIK) for Lantheus Holdings, Inc. is 1521036. Its filings are on SEC EDGAR. How many shares does Lantheus Holdings have outstanding? 65,272,369 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Lantheus Holdings listed under? Our directory records Lantheus Holdings, Inc. under United States. What does Lantheus Holdings do? Our directory classifies Lantheus Holdings, Inc. as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline. What is the ISIN of Lantheus Holdings? The ISIN recorded for Lantheus Holdings, Inc. is US5165441032. Does aibio.space cover Lantheus Holdings? aibio.space lists Lantheus Holdings, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Lantheus Holdings incorporated? SEC records list its state or country of incorporation as DE. Is Lantheus Holdings profitable? Lantheus Holdings, Inc. reported net income of $233.6 million for the fiscal year ended Dec 31, 2025, and generated $390.1 million of cash from operations, per its annual report to the SEC. How much does Lantheus Holdings spend on research and development? $177.3 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Lantheus Holdings have? $593.3 million in cash at Jun 30, 2026, per its 10-Q. What is the latest Lantheus Holdings (LNTH) stock news? Our latest story on Lantheus Holdings, dated Oct 2, 2026: "Lantheus discloses three stockholder suits over its Curium merger and 16 demand letters". Defendants: Lantheus Holdings and unnamed Board members, per the 8-K. Two New York and one Massachusetts complaint allege proxy omissions; the company says they lack merit. [Source](https://aibio.space/news/lantheus-discloses-three-stockholder-suits-curium-merger-16-demand/). Is Lantheus Holdings facing a lawsuit? Our latest legal story, dated Oct 2, 2026: "Lantheus discloses three stockholder suits over its Curium merger and 16 demand letters". Defendants: Lantheus Holdings and unnamed Board members, per the 8-K. Two New York and one Massachusetts complaint allege proxy omissions; the company says they lack merit. Claims in lawsuits are allegations until a court rules. [Source](https://aibio.space/news/lantheus-discloses-three-stockholder-suits-curium-merger-16-demand/). ## Investor discussion: Lantheus Holdings Members talk about Lantheus Holdings (LNTH). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Lantheus Holdings, newest first. Each line links the filing it comes from. 1. 2026-10-02 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1521036/000119312526412563/d31891d8k.htm) 2. 2026-08-03 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1521036/000119312526329622/d148563dex991.htm) 3. 2025-07-22 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1521036/000119312525162233/d89717dex991.htm) 4. 2025-04-01 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1521036/000119312525069927/d905401dex991.htm) 5. 2025-01-13 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1521036/000119312525004904/d860596dex991.htm) 6. 2024-11-20 Financings Announced a share repurchase program. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1521036/000119312524262071/d871395dex991.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:LNTH on TradingView](https://www.tradingview.com/symbols/NASDAQ-LNTH/). ## SEC filings and registration - **SEC name**: Lantheus Holdings, Inc. - **CIK**: 1521036 - **Industry (SIC)**: In Vitro & In Vivo Diagnostic Substances (2835) - **US tickers**: LNTH (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 201 BURLINGTON ROAD, SOUTH BUILDING, BEDFORD, MA, 01730 - **Phone**: 978 671-8001 - **Shares outstanding**: 65,272,369 as of 2026-08-03 (10-Q filed 2026-08-06) - **Former names**: Lantheus MI Holdings, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1521036/000119312526428324/d19181d8k.htm) filed 2026-10-22 - [8-K](https://www.sec.gov/Archives/edgar/data/1521036/000119312526421732/d183496d8k.htm) filed 2026-10-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1521036/000119312526412563/d31891d8k.htm) filed 2026-10-02 - [8-K](https://www.sec.gov/Archives/edgar/data/1521036/000119312526396654/d148743d8k.htm) filed 2026-09-21 - [10-Q](https://www.sec.gov/Archives/edgar/data/1521036/000119312526336795/lnth-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1521036/000119312526336771/lnth-20260806.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1521036/000119312526331138/d167446d8k.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1521036/000119312526329622/d148563d8k.htm) filed 2026-08-03 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001521036), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Lantheus Holdings, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker LNTH, recorded under United States. The directory classifies it as Biopharma / pharmaceuticals. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Lantheus Holdings, Inc. - **Ticker**: LNTH - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biopharma / pharmaceuticals - **ISIN**: US5165441032 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-LNTH/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/lantheus/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Lantheus Holdings (LNTH) news: merger", 2026-10-31, https://aibio.space/companies/lantheus/